A Day Late and a Billion Dollars Short: TMC's Angiomax Patent Nightmare

The Medicines Co. stands to lose $1 billion in revenues from a clerical mistake in a patent extension request; the company, arguing patients will lose, continues to ask Congress to help fix it. But in a Democratic congress, the fight is distinctly uphill.